Method of treating infectious diseases with polysaccharide derivatives
View Patent ↗The present invention relates to a method of treating infectious diseases, that involves: (a) providing an alpha-glycosidically linked starch polysaccharide derivative; and (b) inhibiting the growth of an infectious disease by administering a composition comprising the alpha-glycosidically linked starch polysaccharide derivative. The alpha-glycosidically linked starch polysaccharide derivative represented by the following general formula I, in which: the alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.4 to 2.0; n is 2-4; R 1 is selected from the group consisting of C 1-4 alkyl, benzyl and benzyl substituted with a member selected from the group consisting of C 1-3 alkyl, halogen, alcoxy, carbamoyl, alkoxycarbonyl, cyano, dialkylamino and hydrogen; R 2 and R 3 are each independently selected from the group consisting of C 1-4 alkyl, benzyl and benzyl substituted with a member selected from the group consisting of C 1-3 alkyl, halogen, alcoxy, carbamoyl, alkoxycarbonyl, cyano and dialkylamino; and X is an anion selected from the group consisting of halide, hydroxide, sulfate, hydrogen sulfate and carboxylate.
1. A method of inhibiting the growth of pathogenic bacteria or the replication of herpes or influenza viruses in a patient comprising the step of administering to said patient an amount of an alpha-glycosidically linked starch polysaccharide derivative represented by general formula I,
wherein said alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.4 to 2.0,
n is 2-4,
R 1 is selected from the group consisting of C 1-4 alkyl, benzyl and benzyl substituted with a member selected from the group consisting of C 1-3 alkyl, halogen, alkoxy, carbamoyl, alkoxycarbonyl, cyano, dialkylamino and hydrogen,
R 2 and R 3 are each independently selected from the group consisting of C 1-4 alkyl, benzyl and benzyl substituted with a member selected from the group consisting of C 1-3 alkyl, halogen, alkoxy, carbamoyl, alkoxycarbonyl, cyano and dialkylamino, and
X is an anion selected from the group consisting of halide, hydroxide, sulfate, hydrogen sulfate and carboxylate,
effective to inhibit the growth of said pathogenic bacteria or the replication of said herpes virus or said influenza virus.
2. The method of claim 1 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered at a minimal inhibitory concentration of from 5 to 60 mg/l.
3. The method of claim 1 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered at a minimal inhibitory concentration of from 3 to 50 mg/l.
4. The method of claim 1 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered at a dose of 0.1 to 1000 mg/kg of body weight of said patient.
5. The method of claim 1 wherein said alpha-glycosidically linked starch polysaccharide derivative has a degree of quaternary ammonium group substitution of from 0.6 to 1.8.
6. The method of claim 1 wherein the starch polysaccharide of said alpha-glycosidically linked starch polysaccharide derivative is selected from the group consisting of potato starch, wheat starch, corn starch, rice starch and combinations thereof.
7. The method of claim 1 wherein the starch polysaccharide of said alpha-glycosidically linked starch polysaccharide derivative is selected from the group consisting of starches partially hydrolyzed by chemical means, starches partially hydrolyzed by enzymatic means, starches obtained from genetically modified plants and combinations thereof.
8. The method of claim 1 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered in a form selected from the group consisting of solutions, suspensions, tablets, capsules, suppositories and combinations thereof.
9. The method of claim 8 wherein said alpha-glycosidically linked starch polysaccharide derivative is administered by means selected from the group consisting of parenteral administration, intravenous injection, subcutaneous injection, intramuscular injection, intranasal administration and combinations thereof.
10. The method of claim 1 wherein said pathogenic bacteria are selected from the group consisting of staphylococci and mycobacteria.
11. The method of claim 1 wherein said pathogenic bacteria are staphylococci.
12. The method of claim 11 wherein said pathogenic bacteria are Staphylococcus aureus.
13. The method of claim 1 wherein said pathogenic bacteria are mycobacteria.
14. The method of claim 13 wherein said pathogenic bacteria are Mycobacterium vaccae .